Protalix BioTherapeutics (PLX) Cash from Financing Activities (2010 - 2026)

Protalix BioTherapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $150000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 97.04% year-over-year to $150000.0; the TTM figure through Mar 2026 stood at $4.4 million (down 49.44% YoY), while the FY2025 annual figure was $9.3 million, up 155.53% from the prior year.
• Cash from Financing Activities was $150000.0 for Q1 2026 at Protalix BioTherapeutics, up from $146000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $14.2 million in Q1 2023 to a low of $146000.0 in Q4 2025.
• Historically, Cash from Financing Activities has averaged $4.8 million across 5 years, with a median of $4.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities soared 200.72% in 2022, then tumbled 97.04% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $4.1 million in 2022, then soared by 156.02% to $10.4 million in 2023, then tumbled by 65.24% to $3.6 million in 2024, then plunged by 95.97% to $146000.0 in 2025, then climbed by 2.74% to $150000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $150000.0 (Q1 2026), $146000.0 (Q4 2025), and $4.1 million (Q2 2025), per Business Quant data.